European Peptide Drug Summit 2026

Welcome to the European Peptide Drug Summit 2026, where industry leaders and peptide innovators come together to explore the latest technologies and manufacturing expertise shaping the future of the peptide sector.

The healthcare industry is experiencing a technological transformation in peptide therapeutics, driving the need for improved delivery, stability, and bioavailability. Evolving market demands and regulatory standards are prompting manufacturers to focus on efficacy and precise targeting in the development and production of future therapeutics, ensuring safety and strong clinical outcomes.

Join us to connect with experts, explore innovative strategies, and drive the future of peptide therapeutics to new heights.

Market trends and commercial insights shaping the future of peptide drugs

Analyse market trends across key commercial waves in cardiometabolic, oncology, and delivery platforms to identify growth, partnership, and investment priorities.

Latest advancements and strategies supporting large-scale peptide synthesis

Stay informed on scalable synthesis methods and innovative techniques reshaping manufacturing standards to enhance efficiency, safety, and product quality.

Case studies on peptide applications in radioconjugates and theranostics

Examine real-world case studies on peptide radioconjugate and theranostic platforms, highlighting targeting strategies, clinical outcomes, and translational insights.

AI-driven and tech-powered discovery advancing new peptides and targets

Leverage AI, data-led design, and high-throughput technologies to accelerate peptide lead discovery, validate targets faster, and improve portfolio outcomes.

Applications, formulations, and delivery systems for therapeutic peptides

Learn how novel peptide formulations and innovative delivery technologies are improving therapeutic outcomes and enhancing patient experiences.

Risk-based regulatory approaches and control strategies in peptide drugs

Turn evolving global requirements into an advantage by building robust, risk-based control strategies that support faster approvals and efficient scale-up.

Expert Speakers

Past Attendees

hidden text

hidden text